Skip to main content
Rapid Reactions

Biomarker Testing in mCRC to Help Identify Appropriate Patients for Targeted Treatment

Rapid Reactions
Metastatic Colorectal Cancer
Pashtoon Kasi, MD, MS
Director, Colon Cancer Research, Weill Cornell Medicine
Director, Liquid Biopsy Research, Englander Institute of Precision Medicine
New York, NY
Pashtoon Kasi, MD, MS, from Weill Cornell Medicine and Englander Institute of Precision Medicine, explores potential best practice approaches to biomarker testing in mCRC.

Related Items

Real-world Outcomes Following Initiation of Abemaciclib in Patients With Brain Metastases Secondary to HR+/HER2- Metastatic Breast Cancer
By Hope S. Rugo, MD
Videos
Rapid Reactions
Primary Analysis of HER2CLIMB-02: Addition of Tucatinib to Trastuzumab Emtansine in Previously Treated Patients with HER2-Positive Metastatic Breast Cancer
By Sara M. Tolaney, MD, MPH
Videos
Rapid Reactions
INAVO120 Phase III Study: Treatment of Patients With PIK3CA-mutant, HR+/HER2- Locally Advanced or Metastatic Breast Cancer With Invavolisib in Combination With Palbociclib and Fulvestrant
By Hope S. Rugo, MD
Videos
Rapid Reactions
Abemaciclib and NSAI for 1L Treatment of HR+/HER2- Advanced Breast Cancer: Long-term Survival Data Reported
By Sara M. Tolaney, MD, MPH
Videos
Rapid Reactions